Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.

Introduction: The efficacy of iGlarLixi, a fixed-ratio combination of basal insulin glargine 100 units/mL (iGlar) and the short-acting GLP-1 RA lixisenatide (Lixi), was established in people with type 2 diabetes (T2D) who were advancing therapy from oral antidiabetic drugs (OADs) and basal insulin (BI). This retrospective study aimed to evaluate the effectiveness and safety of iGlarLixi using real-world data from people with T2D in the Adriatic region countries.

Methods: This was a non-interventional, retrospective, multicenter, cohort study with the collection of pre-existing data at iGlarLixi initiation and after 6 months of treatment in real-world clinical and ambulatory settings.

Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.

Background: Two types of fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1RA) have been approved for use in type 2 diabetes. One is insulin degludec/liraglutide (iDergLira), and the other is insulin glargine/lixisenatide (iGlarLixi). Direct comparisons between these two combination is not available.

Correlation of the body mass index and calcium nephrolithiasis in adult population.

Introduction: Prevalence of the kidney stones (renal calculi) increase in several countries in parallel with the increase of overweight, diabetes (type 2 diabetes) and hypertension.

Goal: The goal of our research was to evaluate the connection between the calcium nephrolithiasis and overweight, as quantified using the Body Mass Index (BMI) of the adult population, with a particular reflection on the age groups within it.

Material And Methods: The research was prospective and it was implemented at the Clinical Center of Banja Luka, at the Urology Clinic in the period from 1(st) April 2012 to 1(st) January 2013.